Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Items 201–300 of 864
The hypoxia-inducible factor HIF-1 functions as both a positive and negative modulator of aging
Leiser, S. F., & Kaeberlein, M. (2010) · Biological Chemistry · doi:10.1515/bc.2010.123 · Cited by 75
Tissue, cell and stage specificity of (epi)mutations in cancers
Sieber, O. M., Tomlinson, S. R., & Tomlinson, I. P. M. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1674 · Cited by 77
The von Hippel–Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis
Barry, R. E., & Krek, W. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.07.008 · Cited by 86
Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
Otrock, Z. K., Hatoum, H. A., Awada, A. H., Ishak, R. S., & Shamseddine, A. I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.001 · Cited by 87
MOLECULAR PATHOLOGY OF EYES WITH VON HIPPEL–LINDAU (VHL) DISEASE
Chan, C., Collins, A. B. D., & Chew, E. Y. (2007) · Retina · doi:10.1097/01.iae.0000244659.62202.ee · Cited by 74
Horii, K., Suzuki, Y., Kondo, Y., Akimoto, M., Nishimura, T., Yamabe, Y., Sakaue, M., Sano, T., Kitagawa, T., Himeno, S., et al. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0226 · Cited by 82
Antiangiogenic Therapy for von Hippel-Lindau Disease
Madhusudan, S. (2004) · JAMA · doi:10.1001/jama.291.8.943 · Cited by 75
ATF4 promotes bone angiogenesis by increasing vegf expression and release in the bone environment
Zhu, K., Jiao, H., Li, S., Cao, H., Galson, D. L., Zhao, Z., Zhao, X., Lai, Y., Fan, J., Im, H., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1958 · Cited by 76
Ocular manifestations of von Hippel-Lindau diease: clinical and genetic investigations
Chew, E. Y. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.011 · Cited by 74
Calzada, M. J., Esteban, M. A., Feijoo-Cuaresma, M., Castellanos, M. C., Naranjo-Suárez, S., Temes, E., Méndez, F., Yánez-Mo, M., Ohh, M., & Landázuri, M. O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3236 · Cited by 74
Renal cancer in von Hippel–Lindau disease and related syndromes
Bausch, B., Jilg, C. A., Gläsker, S., Vortmeyer, A. O., Lützen, N., Anton, A., Eng, C., & Neumann, H. P. H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.144 · Cited by 79
Ubiquitin Pathway in VHL Cancer Syndrome
Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06442 · Cited by 76
Liu, M. Y., Poellinger, L., & Walker, C. L. (2003) · PubMed · Cited by 83
Genetics of pheochromocytomas and paragangliomas
Opocher, G., & Schiavi, F. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.001 · Cited by 77
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
Grosfeld, A., Stolze, I. P., Cockman, M. E., Pugh, C. W., Edelmann, M., Kessler, B., Bullock, A. N., Ratcliffe, P. J., & Masson, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611648200 · Cited by 71
VHL Inactivation Induces HEF1 and Aurora Kinase A
Xu, J., Li, H., Wang, B., Xu, Y., Yang, J., Zhang, X., Harten, S. K., Shukla, D., Maxwell, P. H., Pei, D., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040345 · Cited by 71
Review of the Neurological Implications of von Hippel–Lindau Disease
Dornbos, D., Kim, H. J., Butman, J. A., & Lonser, R. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4469 · Cited by 71
Molecular Regulation of Sprouting Angiogenesis
Duran, C. L., Howell, D. W., Dave, J. M., Smith, R. L., Torrie, M. E., Essner, J. J., & Bayless, K. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160048 · Cited by 86
Management of von Hippel-Lindau Disease: An Interdisciplinary Review
Schmid, S., Gillessen, S., Binet, I., Brändle, M., Engeler, D. S., Greiner, J., Hader, C., Heinimann, K., Kloos, P., Krek, W., et al. (2014) · Oncology Research and Treatment · doi:10.1159/000369362 · Cited by 75
Pheochromocytoma in von Hippel–Lindau disease and neurofibromatosis type 1
Opocher, G., Conton, P., Schiavi, F., Macino, B., & Mantero, F. (2005) · Familial Cancer · doi:10.1007/s10689-004-6128-y · Cited by 73
von Hippel–Lindau tumor suppressor: not only HIF's executioner
Czyzyk-Krzeska, M., & Meller, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.004 · Cited by 77
Targeting the Met signaling pathway in renal cancer
Giubellino, A., Linehan, W. M., & Bottaro, D. P. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.43 · Cited by 71
Moore, L. E., Jaeger, E., Nickerson, M. L., Brennan, P., Vries, S. D., Roy, R., Toro, J. R., Li, H., Karami, S., Lenz, P., et al. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.14 · Cited by 82
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
KIM, W., & KAELINJR, W. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.001 · Cited by 79
The von Hippel-Lindau Tumor Suppressor Protein: Roles in Cancer and Oxygen Sensing
Kaelin, W. G. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.001 · Cited by 80
Self-citationHoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
Xiao, X., Tang, C., Xiao, S., Fu, C., & Yu, P. (2012) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13775486749335 · Cited by 70
Nakamura, E., de Abreu-e-Lima, P. C., Awakura, Y., Inoue, T., Kamoto, T., Ogawa, O., Kotani, H., Manabe, T., Zhang, G., Kondo, K., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050867 · Cited by 72
Self-citationThe Contributions of HIF-Target Genes to Tumor Growth in RCC
Zhang, T., Niu, X., Liao, L., Cho, E.-A., & Yang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080544 · Cited by 75
Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease
Lefere, S., Steenkiste, C. V., Verhelst, X., Vlierberghe, H. V., Devisscher, L., & Geerts, A. M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2222-1 · Cited by 77
Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss
Liu, X., Simon, J. M., Xie, H., Hu, L., Wang, J., Zurlo, G., Fan, C., Ptacek, T., Herring, L. E., Tan, X. M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.009 · Cited by 74
Sampson, V. B., David, J. M., Puig, I., Patil, P., de Herreros, A. G., THOMAS, G. V., & Rajasekaran, A. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102041 · Cited by 67
Tumor-Specific Efficacy of Transforming Growth Factor-βRI Inhibition in Eker Rats
Laping, N. J., Everitt, J. I., Frazier, K. S., Burgert, M., Portis, M. J., Cadacio, C., Gold, L. I., & Walker, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1811 · Cited by 67
Genbačev, O., McMaster, M. T., Zdravkovic, T., & Fisher, S. J. (2003) · Reproductive Toxicology · doi:10.1016/s0890-6238(03)00094-7 · Cited by 73
Ocular von Hippel–Lindau disease: clinical update and emerging treatments
Wong, W. T., & Chew, E. Y. (2008) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282fb7c04 · Cited by 66
The Genetic Basis of Pheochromocytoma
Gimm, O., Koch, C. A., Januszewicz, A., Opocher, G., & INeumann, H. P. H. (2003) · KARGER eBooks · doi:10.1159/000074657 · Cited by 70
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
Zecchini, V. R., Madhu, B., Russell, R. R., Pértega‐Gomes, N., Warren, A. Y., Gaude, E., Borlido, J., Stark, R., Zecchini, H. I., Rao, R. B., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386874 · Cited by 66
Tickoo, S. K., Alden, D., Olgac, S., Fine, S. W., Russo, P., Kondagunta, G. V., Motzer, R. J., & Reuter, V. E. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.11.100 · Cited by 65
Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease
Liang, R. H.-S., & Ghaffari, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14194 · Cited by 74
BTB proteins as henchmen of Cul3-based ubiquitin ligases
Krek, W. (2003) · Nature Cell Biology · doi:10.1038/ncb1103-950 · Cited by 65
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 70
Controlling hypoxia-inducible factor-2α is critical for maintaining bone homeostasis in mice
Lee, S. Y., Park, K. H., Yu, H.-G., Kook, E., Song, W., Lee, G., Koh, J., Shin, H., Choi, J., Huh, Y. H., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0054-y · Cited by 64
Sudarshan, S., Pinto, P. A., Neckers, L., & Linehan, W. M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0711 · Cited by 65
Kim, J., Rini, B. I., & Hansel, D. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_22 · Cited by 66
From kidney injury to kidney cancer
Peired, A. J., Lazzeri, E., Guzzi, F., Anders, H., & Romagnani, P. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.011 · Cited by 66
Shanmugasundaram, K., Nayak, B., Shim, E., Livi, C. B., Block, K. L., & Sudarshan, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568162 · Cited by 66
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases
Zurlo, G., Guo, J., Takada, M., Wei, W., & Zhang, Q. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.004 · Cited by 61
Barontini, M., & Dahia, P. L. M. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.01.002 · Cited by 73
Fibronectin is a hypoxia‐independent target of the tumor suppressor VHL
Bluyssen, H. A. R., Lolkema, M. P., van Beest, M., Boone, M., Snijckers, C. M. J. T., Los, M., Gebbink, M. F. B. G., Braam, B. G., Holstege, F. C. P., Giles, R. H., et al. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01392-9 · Cited by 68
Lee, Y., Vortmeyer, A. O., Lubensky, I. A., Vogel, T. W. A., Ikejiri, B. L., Ferlicot, S., Benoît, G., Giraud, S., Oldfield, E. H., Linehan, W. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1059.11.3 · Cited by 60
Ivanov, S. V., Ivanova, A. V., Salnikow, K., Timofeeva, O. A., Subramaniam, M., & Lerman, M. I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.066 · Cited by 59
Linehan, W. M., Rubin, J. S., & Bottaro, D. P. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.024 · Cited by 59
Wick, C. C., Manzoor, N. F., Semaan, M. T., Megerian, C. A., & Mowry, S. E. (2015) · Springer eBooks · doi:10.1007/978-3-032-18264-7_70 · Cited by 59
Knudsen, E. S., Balaji, U., Freinkman, E., McCue, P. A., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11893 · Cited by 64
Activation of HIF-prolyl Hydroxylases by R59949, an Inhibitor of the Diacylglycerol Kinase
Temes, E., Martín-Puig, S., Acosta‐Iborra, B., Castellanos, M. C., Feijoo‐Cuaresma, M., Olmos, G., Aragonés, J., & Landázuri, M. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414694200 · Cited by 64
Pietras, A., Johnsson, A. S., & Påhlman, S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_72 · Cited by 68
Nervous system involvement in von Hippel–Lindau disease: pathology and mechanisms
Vortmeyer, A. O., Falke, E., Gläsker, S., Li, J., & Oldfield, E. H. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1091-z · Cited by 62
NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL
Russell, R. C., & Ohh, M. (2008) · EMBO Reports · doi:10.1038/embor.2008.19 · Cited by 69
Bussolati, B., Dekel, B., Azzarone, B. G., & Camussi, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.007 · Cited by 59
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris, M. R., Hughes, D. J., Tian, Y.-M., Ricketts, C. J., Lau, K. W., Gentle, D., Shuib, S., Serrano‐Fernández, P., Lubiński, J., Wiesener, M. S., et al. (2009) · PubMed · Cited by 69
USP37 promotes deubiquitination of HIF2α in kidney cancer
Hong, K., Hu, L., Liu, X., Simon, J. M., Ptacek, T., Zheng, X., Liao, C., Baldwin, A. S., & Zhang, Q. H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002567117 · Cited by 64
Ghosh, R., Samanta, P., Sarkar, R., Biswas, S., Saha, P., Hajra, S., & Bhowmik, A. (2022) · Molecules · doi:10.3390/molecules27165192 · Cited by 248
Forman, J., Worth, C. L., Bickerton, G. R., Eisen, T. G., & Blundell, T. L. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22419 · Cited by 64
Biswas, S., Charlesworth, P. J. S., Turner, G. D. H., Leek, R., Thamboo, P. T., Campo, L., Turley, H., Dildey, P., Protheroe, A. S., Cranston, D., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs222 · Cited by 65
Taïeb, D., Yang, C., Delenne, B., Zhuang, Z., Barlier, A., Sebag, F., & Pacak, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1217 · Cited by 55
Yang, B., Riccardo Autorino, B., Remer, E. M., Laydner, H. K., Hillyer, S. P., Altunrende, F., White, M. A., Khanna, R., Stein, R. J., Haber, G., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.05.008 · Cited by 56
Shang, D., Liu, Y., Yang, P., Chen, Y., & Tian, Y. (2012) · Urology · doi:10.1016/j.urology.2011.12.011 · Cited by 57
McMahon, K., Findeis, S. K., & Findeis-Hosey, J. J. (2016) · Journal of Pediatric Genetics · doi:10.1055/s-0036-1579757 · Cited by 55
Indo, H. P., Hawkins, C. L., Nakanishi, I., Matsumoto, K., Matsui, H., Suenaga, S., Davies, M. J., Clair, D. K. S., Ozawa, T., & Majima, H. J. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_117 · Cited by 59
Targeting HIF2 in Clear Cell Renal Cell Carcinoma
Cho, H., & Kaelin, W. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030833 · Cited by 56
Self-citationUtility of Immunohistochemistry in the Pancreatobiliary Tract
Lin, F., Chen, Z. E., & Wang, H. L. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0072-ra · Cited by 55
Fielding, J. W., Hodson, E. J., Cheng, X., Ferguson, D. J. P., Eckardt, L., Adam, J., Lip, P., Maton‐Howarth, M., Ratnayaka, I., Pugh, C. W., et al. (2018) · The Journal of Physiology · doi:10.1113/jp275996 · Cited by 60
Bernards, R. (2003) · Nature · doi:10.1038/425247a · Cited by 55
TRiC/CCT Chaperonin: Structure and Function
Jin, M., Liu, C., Han, W., & Cong, Y. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-28151-9_19 · Cited by 62
Von Hippel-Lindau Disease: A Genetic and Clinical Review
Haddad, N. M. N., Cavallerano, J. D., & Silva, P. S. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825281 · Cited by 56
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
Královics, R., & Skoda, R. C. (2004) · Blood Reviews · doi:10.1016/j.blre.2004.02.002 · Cited by 72
Capitanio, J. F., Mazza, E. A., Motta, M., Mortini, P., & Reni, M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.10.001 · Cited by 53
VHL promotes immune response against renal cell carcinoma via NF-κB–dependent regulation of VCAM-1
Labrousse-Arias, D., Martínez‐Alonso, E., Corral-Escariz, M., Bienes-Martínez, R., Berridy, J., Serrano‐Oviedo, L., Conde, E., García‐Bermejo, L., Bachs, J. M. G., Sánchez, A. S. S., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201608024 · Cited by 57
The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia
Hatzimichael, E. C., Dasoula, A., Shah, R., Syed, N., Papoudou‐Bai, A., Coley, H. M., Dranitsaris, G., Bourantas, K. L., Stebbing, J., & Crook, T. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01344.x · Cited by 58
Kivela, A.-J., Parkkila, S., Saarnio, J., Karttunen, T.-J., Kivela, J., Parkkila, A.-K., Bartosova, M., Mucha, V., Novak, M., Waheed, A., et al. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i17.2616 · Cited by 58
Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
Yu, J., Wang, S., Shi, W., Zhou, W., Niu, Y., Huang, S., Zhang, Y., Zhang, A., & Jia, Z. (2021) · JCI Insight · doi:10.1172/jci.insight.133690 · Cited by 61
Daniels, A. B., Tirosh, A., Huntoon, K., Mehta, G. U., Spiess, P. E., Friedman, D. L., Waguespack, S. G., Kilkelly, J. E., Rednam, S., Pruthi, S., et al. (2023) · Cancer · doi:10.1002/cncr.34896 · Cited by 61
Albiñana, V., Heras, K. V. G. D. L., Serrano‐Heras, G., Segura, T., Moratalla, A. B. P., Mota-Pérez, M., de Campos, J. M., & Botella, L. M. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0343-5 · Cited by 58
Gervais, M. L., Henry, P., Saravanan, A., Burry, T. N., Gallie, B. L., Jewett, M. A. S., Hill, R. P., Evans, A. J., & Ohh, M. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700684 · Cited by 51
The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours
Pipinikas, C., Berner, A., Sposito, T., & Thirlwell, C. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0175 · Cited by 55
Genetic Basis of Cancer of the Kidney
Sudarshan, S., & Linehan, W. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.008 · Cited by 56
TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3
Pery, E., Tsruya, R., Levitsky, P., Pomp, O., Taler, M., Weisberg, S., Parris, W. E., Kulkarni, S., Malovani, H., Pawson, T. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208149 · Cited by 56
Zhou, L., & Yang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023936 · Cited by 61
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma
Doberstein, K., Pfeilschifter, J. M., & Gutwein, P. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr195 · Cited by 62
Fay, M. J., Longo, K. A., Karathanasis, G. A., Shope, D. M., Mandernach, C. J., Leong, J. R., Hicks, A., Pherson, K., & Husain, A. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-40 · Cited by 52
Von Hippel-Lindau disease: an evaluation of natural history and functional disability
Feletti, A., Anglani, M., Scarpa, B., Schiavi, F., Boaretto, F., Zovato, S., Taschin, E., Gardi, M., Zanoletti, E., Piermarocchi, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov313 · Cited by 51
Restriction of rRNA Synthesis by VHL Maintains Energy Equilibrium under Hypoxia
Mekhail, K., Rivero-Lopez, L., Khacho, M., & Lee, S. (2006) · Cell Cycle · doi:10.4161/cc.5.20.3387 · Cited by 50
Small molecule regulators of Rb–E2F pathway as modulators of transcription
Singh, S., Johnson, J. L., & Chellappan, S. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.07.004 · Cited by 58
Womeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 52
Prolyl Hydroxylase PHD3 Enhances the Hypoxic Survival and G1 to S Transition of Carcinoma Cells
Högel, H., Rantanen, K., Jokilehto, T., Grenman, R. A., & Jaakkola, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027112 · Cited by 54
Targeting the A2AR in cancer; early lessons from the clinic
Willingham, S. B., Hotson, A. N., & Miller, R. A. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.003 · Cited by 47
Fumarate Hydratase Deficiency and Cancer: Activation of Hypoxia Signaling?
Ratcliffe, P. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.015 · Cited by 51
Lucas, J. E., Kung, H.-N., & Chi, J.-T. A. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000920 · Cited by 49
Deregulation of E2-EPF Ubiquitin Carrier Protein in Papillary Renal Cell Carcinoma
Roos, F. C., Evans, A. J., Brenner, W., Wondergem, B., Klomp, J., Heir, P., Roche, O., Thomas, C., Schimmel, H., Furge, K. A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.033 · Cited by 52
Activation of hypoxia-induced transcription in normoxia
Hägg, M., & Wennström, S. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.017 · Cited by 57
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.